<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>Type 2 Diabetes – One‑Page Clinical Algorithm (CKS 2025)</title>
  <meta name="color-scheme" content="light dark" />
  <style>
    /* ------------------
       Design System
    ------------------ */
    :root{
      --bg: #0b0c0f;                /* fallback for dark */
      --panel: #12141a;
      --ink: #e9eef7;
      --muted: #b9c2d0;
      --brand: #5eead4;            /* teal */
      --brand-2:#93c5fd;           /* soft blue */
      --accent:#a78bfa;            /* purple */
      --ok:#34d399;                /* green */
      --warn:#f59e0b;              /* amber */
      --danger:#f87171;            /* red */
      --border: color-mix(in oklab, var(--ink) 10%, transparent);
      --ring: color-mix(in oklab, var(--brand) 60%, transparent);
      --radius: 18px;
      --shadow: 0 10px 25px rgba(0,0,0,.35);
      --maxw: 1180px;
    }
    @media (prefers-color-scheme: light){
      :root{
        --bg:#f7fafc;
        --panel:#ffffff;
        --ink:#0d1321;
        --muted:#4b5563;
        --border:#e5e7eb;
        --shadow: 0 10px 25px rgba(2,6,23,.08);
      }
    }

    *{box-sizing:border-box}
    html,body{height:100%}
    body{
      margin:0;
      background:linear-gradient(135deg, color-mix(in oklab, var(--panel) 65%, var(--bg)), var(--bg));
      color:var(--ink);
      font: 400 clamp(14px, .95vw + 10px, 18px)/1.6 system-ui, -apple-system, Segoe UI, Roboto, Inter, "Helvetica Neue", Arial, "Noto Sans", "Apple Color Emoji", "Segoe UI Emoji";
      letter-spacing:.2px;
    }

    /* Layout */
    .app{display:grid; grid-template-columns: 280px 1fr; gap:28px; max-width:var(--maxw); margin:auto; padding:24px;}
    nav{
      position: sticky; top:16px; align-self: start;
      background:var(--panel); border:1px solid var(--border); border-radius:var(--radius);
      box-shadow:var(--shadow); padding:18px; height: max-content;
    }
    nav h2{margin:.25rem 0 1rem; font-size:1.05rem; color:var(--muted); font-weight:600; letter-spacing:.3px}
    nav a{
      display:block; padding:10px 12px; margin:4px 0; border-radius:12px; text-decoration:none; color:var(--ink);
      border:1px solid transparent;
    }
    nav a:hover{background:color-mix(in oklab, var(--brand) 12%, transparent); border-color:var(--ring)}
    nav .minor{color:var(--muted); margin-top:12px; font-size:.9rem}

    header.hero{
      grid-column: 1 / -1; background:radial-gradient(80% 100% at 0% 0%, color-mix(in oklab, var(--brand) 18%, transparent), transparent),
                                  radial-gradient(60% 100% at 100% 0%, color-mix(in oklab, var(--accent) 18%, transparent), transparent);
      border-radius:calc(var(--radius) + 4px);
      border:1px solid var(--border);
      box-shadow:var(--shadow);
      padding:28px 28px 22px; position:relative; overflow:hidden;
    }
    .kicker{display:inline-flex; align-items:center; gap:10px; padding:6px 10px; border-radius:999px; border:1px solid var(--border); background:var(--panel); color:var(--muted); font-weight:600; font-size:.9rem}
    .kicker svg{width:18px; height:18px}
    .title{
      margin:.6rem 0 0; font-size:clamp(1.5rem, 1.4rem + 1.5vw, 2.2rem); font-weight:800; letter-spacing:.2px;
    }
    .subtitle{color:var(--muted); margin:.2rem 0 0; max-width:70ch}

    .grid{display:grid; grid-template-columns: repeat(12, 1fr); gap:22px; margin-top:22px}

    .card{
      background:var(--panel); border:1px solid var(--border); border-radius:var(--radius); box-shadow:var(--shadow);
      padding:18px 18px 16px; position:relative; overflow:hidden
    }
    .card .h{display:flex; align-items:center; gap:10px; margin-bottom:10px}
    .card .h svg{width:22px; height:22px}
    .card h3{margin:0; font-size:1.05rem; letter-spacing:.3px}
    .pill{display:inline-block; font-size:.78rem; font-weight:700; letter-spacing:.3px; padding:4px 8px; border-radius:999px; border:1px solid var(--border); color:var(--muted);}
    .muted{color:var(--muted)}
    .list{margin:.45rem 0 0; padding-left:1.1rem}
    .list li{margin:.25rem 0}
    .grid .span-6{grid-column: span 6}
    .grid .span-4{grid-column: span 4}
    .grid .span-8{grid-column: span 8}
    .grid .span-12{grid-column: 1 / -1}

    /* Emphasis chips */
    .chip{display:inline-flex; align-items:center; gap:8px; border:1px dashed var(--border); padding:6px 10px; border-radius:10px; margin:6px 6px 0 0}
    .chip.ok{background:color-mix(in oklab, var(--ok) 15%, transparent)}
    .chip.warn{background:color-mix(in oklab, var(--warn) 15%, transparent)}
    .chip.danger{background:color-mix(in oklab, var(--danger) 15%, transparent)}

    /* Tables */
    .table{width:100%; border-collapse:separate; border-spacing:0; overflow:hidden; border-radius:14px; border:1px solid var(--border)}
    .table th, .table td{padding:10px 12px; text-align:left}
    .table thead th{font-size:.88rem; color:var(--muted); border-bottom:1px solid var(--border); background:color-mix(in oklab, var(--brand) 10%, var(--panel))}
    .table tbody tr + tr td{border-top:1px dashed var(--border)}

    /* Utilities */
    .note{font-size:.92rem}
    .badge{display:inline-block; padding:2px 8px; font-size:.72rem; border-radius:999px; border:1px solid var(--border); color:var(--muted)}
    .cols{columns:2; column-gap:22px}
    .cols p, .cols ul{break-inside:avoid}

    /* Footer & print */
    footer{grid-column:1/-1; color:var(--muted); font-size:.9rem; margin:8px 0 6px}
    @media (max-width: 980px){
      .app{grid-template-columns: 1fr}
      nav{position:relative}
      .grid .span-6, .grid .span-4, .grid .span-8{grid-column: 1 / -1}
      .cols{columns:1}
    }
    @media print{
      body{background:white; color:black}
      nav, .kicker, .subtitle, footer{display:none}
      .app{padding:0}
      .card{box-shadow:none; border:1px solid #999}
    }
  </style>
</head>
<body>
  <a href="#main" class="badge" style="position:absolute;left:-999px;top:auto;width:1px;height:1px;overflow:hidden">Skip to content</a>
  <div class="app">

    <header class="hero" id="top">
      <div class="kicker" title="Clinical quick‑reference">
        <!-- spark icon -->
        <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="1.5"><path d="M12 2v6M12 16v6M4.93 4.93l4.24 4.24M14.83 14.83l4.24 4.24M2 12h6M16 12h6M4.93 19.07l4.24-4.24M14.83 9.17l4.24-4.24"/></svg>
        Type 2 Diabetes · One‑Page Algorithm — NICE CKS (July 2025)
      </div>
      <h1 class="title">Rapid Decision Aid for Primary Care</h1>
      <p class="subtitle">Concise, stepwise pathway for diagnosis, targets, pharmacologic escalation, complication screening, and special populations. Designed for quick recall in consultations and to print on a single page.</p>
    </header>

    <nav aria-label="Section navigation">
      <h2>Navigate</h2>
      <a href="#diagnosis">Diagnosis</a>
      <a href="#hba1c">HbA1c Interpretation</a>
      <a href="#targets">Treatment Targets</a>
      <a href="#pharmacology">Stepwise Pharmacology</a>
      <a href="#lifestyle">Lifestyle Advice</a>
      <a href="#monitoring">Monitoring & Screening</a>
      <a href="#cv">Cardiovascular Risk</a>
      <a href="#emergencies">DKA / HHS</a>
      <a href="#sickday">Sick‑day Rules</a>
      <a href="#cyp">Children & Young People</a>
      <a href="#resources">Resources</a>
      <div class="minor">Tip: Press <strong>Ctrl/Cmd + P</strong> for a print‑optimized version.</div>
    </nav>

    <main id="main">
      <section id="diagnosis" class="grid">
        <div class="card span-6">
          <div class="h"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="1.5"><path d="M21 15a4 4 0 1 1-8 0 4 4 0 0 1 8 0ZM3 4h7m-7 4h7M3 12h7M3 16h7"/></svg><h3>Diagnosis — Adults</h3><span class="pill">Confirm if asymptomatic</span></div>
          <ul class="list">
            <li>Suspect T2DM with persistent hyperglycaemia + risk factors/symptoms (polyuria, polydipsia, weight loss, recurrent infections, tiredness, blurred vision; acanthosis nigricans).</li>
            <li><strong>Diagnostic thresholds</strong>: HbA1c ≥ <strong>48</strong> mmol/mol (6.5%); FPG ≥ <strong>7.0</strong> mmol/L; RPG ≥ <strong>11.1</strong> mmol/L with symptoms.</li>
            <li>If asymptomatic, repeat the same test to confirm; note transient hyperglycaemia in acute illness.</li>
          </ul>
        </div>
        <div class="card span-6">
          <div class="h"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="1.5"><path d="M12 3v18m9-9H3"/></svg><h3>Diagnosis — Children & Young People</h3><span class="pill">Same‑day referral</span></div>
          <ul class="list">
            <li>Assume <strong>type 1</strong> unless strong T2DM indicators (obesity, acanthosis, family/ethnic risk).</li>
            <li>Thresholds: FPG ≥ <strong>7.0</strong> mmol/L; RPG ≥ <strong>11.1</strong> mmol/L with symptoms; HbA1c ≥ <strong>48</strong> mmol/mol.</li>
            <li><strong>Refer immediately the same day</strong> to a multidisciplinary paediatric diabetes team to confirm diagnosis & start care.</li>
          </ul>
        </div>
      </section>

      <section id="hba1c" class="grid">
        <div class="card span-12">
          <div class="h"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="1.5"><path d="M4 4h16v6H4zM4 14h16v6H4z"/></svg><h3>When <em>not</em> to use HbA1c for diagnosis / interpret with caution</h3><span class="pill">Choose plasma glucose instead</span></div>
          <div class="cols">
            <ul class="list">
              <li>Under 18 years; pregnancy or ≤2 months postpartum; symptoms &lt; 2 months; acutely ill; on hyperglycaemia‑inducing meds (e.g., long‑term steroids); acute pancreatic damage; ESRD.</li>
            </ul>
            <ul class="list">
              <li>Caution with abnormal RBC turnover/haemoglobin (e.g., haemoglobinopathies incl. sickle trait), severe anaemia, altered RBC lifespan (post‑splenectomy), recent transfusion.</li>
            </ul>
          </div>
        </div>
      </section>

      <section id="targets" class="grid">
        <div class="card span-6">
          <div class="h"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="1.5"><path d="M12 3v18M3 12h18"/></svg><h3>Treatment Targets (Adults)</h3><span class="pill">Measure q3–6 months, then q6 months</span></div>
          <table class="table">
            <thead><tr><th>Context</th><th>Target HbA1c</th></tr></thead>
            <tbody>
              <tr><td>Diet ± single agent not causing hypo (e.g., metformin)</td><td><strong>48 mmol/mol</strong> (6.5%)</td></tr>
              <tr><td>Therapy with hypo risk (e.g., sulfonylurea/insulin)</td><td><strong>53 mmol/mol</strong> (7.0%)</td></tr>
            </tbody>
          </table>
          <p class="note">If HbA1c ≥ <strong>58</strong> mmol/mol (7.5%) on a single drug: reinforce lifestyle, check adherence, aim for 53, and <strong>intensify</strong> therapy.</p>
        </div>
        <div class="card span-6">
          <div class="h"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="1.5"><path d="M5 12l4 4L19 6"/></svg><h3>Self‑monitoring</h3><span class="pill">Not routine</span></div>
          <ul class="list">
            <li>Do <strong>not</strong> routinely recommend SMBG.</li>
            <li>Indications: insulin therapy; evidence of hypoglycaemia; starting steroids; suspected hypos; driving where SMBG is required by DVLA.</li>
          </ul>
        </div>
      </section>

      <section id="pharmacology" class="grid">
        <div class="card span-12">
          <div class="h"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="1.5"><path d="M4 8h16M4 16h16M12 2v20"/></svg><h3>Stepwise Pharmacology (Adults)</h3><span class="pill">Individualise by CV/renal status, weight, hypoglycaemia risk, preferences</span></div>
          <div class="cols">
            <div>
              <p><strong>1) First‑line</strong></p>
              <ul class="list">
                <li><strong>Metformin (standard‑release)</strong> and up‑titrate; switch to modified‑release if GI intolerance.</li>
                <li>Assess CV status:
                  <ul>
                    <li><strong>Established ASCVD / Heart failure</strong>: add <strong>SGLT2 inhibitor with CV benefit</strong> to metformin.</li>
                    <li><strong>High CV risk</strong>: consider adding <strong>SGLT2 inhibitor</strong>.</li>
                  </ul>
                </li>
                <li>If metformin <em>contraindicated/intolerant</em>:
                  <ul>
                    <li>ASCVD/HF/high risk → <strong>SGLT2 inhibitor</strong>.</li>
                    <li>Otherwise → choose <strong>DPP‑4 inhibitor</strong>, <strong>pioglitazone</strong>, or <strong>sulfonylurea</strong>.</li>
                  </ul>
                </li>
              </ul>

              <p><strong>2) If monotherapy inadequate</strong></p>
              <ul class="list">
                <li>Add one of: <strong>DPP‑4 inhibitor</strong>, <strong>pioglitazone</strong>, <strong>sulfonylurea</strong>, or <strong>SGLT2 inhibitor</strong> (especially if SU contraindicated/not tolerated or high hypo risk).</li>
              </ul>

              <p><strong>3) If dual therapy inadequate</strong></p>
              <ul class="list">
                <li><strong>Triple therapy</strong>: add one of DPP‑4i / pioglitazone / SU / SGLT2i.</li>
                <li>Specifics: 
                  <ul>
                    <li><strong>Canagliflozin</strong> or <strong>empagliflozin</strong>: with metformin + (DPP‑4i or SU or pioglitazone).</li>
                    <li><strong>Dapagliflozin</strong>: with <strong>metformin + SU</strong> (not with pioglitazone).</li>
                    <li><strong>Ertugliflozin</strong>: with <strong>metformin + DPP‑4i</strong> if SU/pioglitazone not appropriate.</li>
                  </ul>
                </li>
              </ul>
            </div>
            <div>
              <p><strong>4) GLP‑1 Receptor Agonist (switch one drug)</strong></p>
              <ul class="list">
                <li>Consider if: 
                  <ul>
                    <li><strong>BMI ≥ 35</strong> kg/m² (adjust for ethnicity) with obesity‑related issues, or</li>
                    <li><strong>BMI &lt; 35</strong> and insulin has occupational implications, or weight loss would benefit obesity‑related comorbidities.</li>
                  </ul>
                </li>
                <li><em>Continue only if</em> ≥11 mmol/mol (1.0%) HbA1c reduction <em>and</em> ≥3% weight loss at 6 months.</li>
                <li>If adding to insulin/SU, consider reducing insulin secretagogue dose to limit hypoglycaemia.</li>
                <li><strong>Stop DPP‑4 inhibitor</strong> when starting GLP‑1 RA (no added glycaemic benefit).</li>
              </ul>

              <p><strong>5) Insulin</strong></p>
              <ul class="list">
                <li>Consider if symptomatic hyperglycaemia or failure of oral/GLP‑1 RA therapy; initiate with specialist support.</li>
                <li>GLP‑1 RA + insulin only with consultant‑led team oversight.</li>
              </ul>

              <div class="chip ok">Choose lowest acquisition‑cost options where clinically appropriate.</div>
              <div class="chip warn">Match renal function & interactions (e.g., SGLT2 peri‑illness, metformin in AKI risk).</div>
            </div>
          </div>
        </div>
      </section>

      <section id="lifestyle" class="grid">
        <div class="card span-8">
          <div class="h"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="1.5"><path d="M4 20v-8a8 8 0 1 1 16 0v8M9 21h6"/></svg><h3>Lifestyle Advice (Adults)</h3><span class="pill">Offer structured education (e.g., DESMOND)</span></div>
          <ul class="list">
            <li><strong>Diet:</strong> high‑fibre, low‑GI carbs; oily fish; limit saturated/trans fat, salt, and sugary drinks; tailor carbs/alcohol & meal pattern; discourage “diabetic foods”.</li>
            <li><strong>Weight:</strong> initial goal <strong>5–10%</strong> loss (smaller losses still beneficial).</li>
            <li><strong>Physical activity:</strong> regular exercise; minimise sedentary time; integrate with nutrition for weight/CV risk benefits.</li>
            <li><strong>Alcohol:</strong> stay within limits; carb snack before/after; delayed hypoglycaemia possible.</li>
            <li><strong>Smoking:</strong> cessation support; discuss complications risk.</li>
          </ul>
        </div>
        <div class="card span-4">
          <div class="h"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="1.5"><path d="M12 6v6l4 2"/></svg><h3>Immunisation & Support</h3><span class="pill">At/near diagnosis</span></div>
          <ul class="list">
            <li>Offer influenza & pneumococcal vaccination.</li>
            <li>Provide contact route for diabetes team; signpost Diabetes UK resources.</li>
            <li>Discuss contraception & pre‑pregnancy counselling where relevant.</li>
          </ul>
        </div>
      </section>

      <section id="monitoring" class="grid">
        <div class="card span-12">
          <div class="h"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="1.5"><path d="M4 4h16v16H4zM8 8h8v8H8z"/></svg><h3>Monitoring & Screening — Annual Care Processes</h3><span class="pill">Coordinate at diagnosis and yearly</span></div>
          <div class="cols">
            <ul class="list">
              <li><strong>Eyes:</strong> diabetic retinopathy screening.</li>
              <li><strong>Feet:</strong> pulses, sensation, deformity, skin; risk classification & education.</li>
              <li><strong>Kidneys:</strong> UACR (first‑void AM preferred) and eGFR; confirm microalbuminuria with 2 further tests.</li>
              <li><strong>Neuropathy:</strong> ask for distal sensory symptoms; check for autonomic features if indicated.</li>
            </ul>
            <ul class="list">
              <li><strong>BP:</strong> treat per HTN guideline; ACEi/ARB first‑line with CKD/albuminuria; manage resistant HTN per protocol.</li>
              <li><strong>Lipids:</strong> see CV risk section; aim &gt;40% non‑HDL reduction.</li>
              <li><strong>Vaccines, psychosocial, education:</strong> refresh annually.</li>
            </ul>
          </div>
        </div>
      </section>

      <section id="cv" class="grid">
        <div class="card span-6">
          <div class="h"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="1.5"><path d="M12 21s-7-4.35-7-10A5 5 0 0 1 12 6a5 5 0 0 1 7 5c0 5.65-7 10-7 10z"/></svg><h3>Lipid Modification</h3><span class="pill">Statin first‑line</span></div>
          <ul class="list">
            <li><strong>No established CVD</strong>: Atorvastatin <strong>20 mg nocte</strong> if ≤84 yrs and QRISK10 ≥10%, or age ≥85 (consider comorbidity/frailty), or CKD.</li>
            <li><strong>Established CVD</strong>: Atorvastatin <strong>80 mg nocte</strong> for secondary prevention.</li>
            <li><strong>Goal</strong>: &gt;40% reduction in non‑HDL cholesterol; consider up‑titration if not achieved.</li>
          </ul>
        </div>
        <div class="card span-6">
          <div class="h"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="1.5"><path d="M4 12h16M12 4v16"/></svg><h3>Antihypertensives & Antiplatelets</h3><span class="pill">Safety first</span></div>
          <ul class="list">
            <li>Start/optimise per HTN guideline (ACEi/ARB pivotal with albuminuria/CKD). Escalate with CCB and thiazide‑like diuretic; confirm true resistance before 4th agent.</li>
            <li><strong>Do not</strong> offer routine aspirin/clopidogrel for <strong>primary prevention</strong> in T2DM.</li>
          </ul>
        </div>
      </section>

      <section id="emergencies" class="grid">
        <div class="card span-6">
          <div class="h"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="1.5"><path d="M12 2l9 7-3 11H6L3 9l9-7z"/></svg><h3>Diabetic Ketoacidosis (DKA)</h3><span class="pill">Emergency → admit</span></div>
          <ul class="list">
            <li>Consider with known diabetes or BG &gt;11 mmol/L + polyuria/polydipsia, abdo pain, vomiting, Kussmaul breathing, dehydration, drowsiness.</li>
            <li>Check ketones: blood &gt; <strong>3.0</strong> mmol/L or urine ≥ <strong>2+</strong>. <em>Low ketones do not always exclude DKA.</em></li>
            <li>Risk even with near‑normal glucose in insulin users and <strong>SGLT2 inhibitors</strong> (euglycaemic DKA).</li>
          </ul>
        </div>
        <div class="card span-6">
          <div class="h"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="1.5"><path d="M3 12h18M12 3v18"/></svg><h3>Hyperosmolar Hyperglycaemic State (HHS)</h3><span class="pill">Emergency → admit</span></div>
          <ul class="list">
            <li>Older, comorbid; prolonged severe hyperglycaemia (BG typically <strong>&gt;30</strong> mmol/L), profound dehydration, confusion/drowsiness.</li>
            <li>Minimal/no ketosis on testing.</li>
            <li>Precipitants: infection, missed insulin, acute illness, steroids/diuretics/atypical antipsychotics, physiological stress (surgery/trauma).</li>
          </ul>
        </div>
      </section>

      <section id="sickday" class="grid">
        <div class="card span-12">
          <div class="h"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="1.5"><path d="M3 12a9 9 0 1 1 18 0A9 9 0 0 1 3 12Zm7-3h4m-6 6h2m2 0h2"/></svg><h3>Sick‑day Rules (Adults)</h3><span class="pill">Prevent AKI & DKA</span></div>
          <div class="cols">
            <ul class="list">
              <li>Maintain hydration & carbohydrates; never stop insulin without specialist advice.</li>
              <li><strong>Pause</strong> <em>metformin</em> and <em>SGLT2 inhibitors</em> during acute illness, dehydration, or pre‑op; check blood ketones if unwell or eating/drinking poorly.</li>
            </ul>
            <ul class="list">
              <li>Increase glucose monitoring if on insulin or SU; seek urgent help for persistent vomiting, ketones, or reduced consciousness.</li>
            </ul>
          </div>
        </div>
      </section>

      <section id="cyp" class="grid">
        <div class="card span-12">
          <div class="h"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="1.5"><path d="M5 20V6a3 3 0 0 1 3-3h8a3 3 0 0 1 3 3v14M7 9h10M7 13h10M7 17h6"/></svg><h3>Children & Young People (12 months–17 years)</h3><span class="pill">Specialist‑led care</span></div>
          <div class="cols">
            <ul class="list">
              <li><strong>Diagnosis:</strong> same thresholds as adults; assume T1DM unless strong T2DM features; <strong>same‑day referral</strong> to paediatric diabetes team.</li>
              <li><strong>Targets:</strong> HbA1c <strong>≤48</strong> mmol/mol (6.5%); measure <strong>every 3 months</strong>; individualise lowest safe target.</li>
              <li><strong>Therapy:</strong> paediatric team initiates; start <strong>metformin</strong> from diagnosis; <strong>insulin</strong> may be required.</li>
            </ul>
            <ul class="list">
              <li><strong>Screening:</strong> annual retinopathy, foot assessment, kidney (UACR), BP (ABPM to confirm HTN), and lipids (TC, HDL, non‑HDL, TG; confirm on repeat).</li>
              <li><strong>Transition:</strong> anticipate HbA1c drift; address insulin resistance from puberty, erratic routines, and adherence; support education & lifestyle.</li>
            </ul>
          </div>
        </div>
      </section>

      <section id="resources" class="grid">
        <div class="card span-12">
          <div class="h"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="1.5"><path d="M4 4h16v4H4zM4 10h16v10H4z"/></svg><h3>Resources & Notes</h3><span class="pill">Use alongside local formulary</span></div>
          <ul class="list">
            <li>Offer structured education (e.g., DESMOND). Reinforce annually.</li>
            <li>Provide patient support links (e.g., Diabetes UK) and advise carrying medical ID.</li>
            <li>This sheet summarises NICE CKS (July 2025). Always individualise for comorbidity, frailty, and risk of hypoglycaemia.</li>
          </ul>
        </div>
      </section>

    </main>

    <footer>
      <p>© Your Clinic • Quick‑reference aid based on NICE Clinical Knowledge Summaries (CKS) 2025. For clinical use by trained professionals. Check contraindications, interactions, renal thresholds and local guidance.</p>
    </footer>

  </div>
</body>
</html>
